Tag: DurAVR transcatheter heart valve
$38.5M investment to expand Anteris’ manufacturing capacity, global clinical program
Anteris Technologies Global Corp has announced a binding agreement for a private placement valued at approximately AUD 38.5 million (USD 25.2 million) to support the advancement of its PARADIGM clinical trial and accelerate global commercialisation efforts.
Anteris granted utility patent for heart valve replacement technology
Australian biotechnology company Anteris Technologies announced that the United States Patent and Trademark Office has issued a utility patent for its novel DurAVR transcatheter heart valve (THV).
Featured Article
How growth capital is helping an Australian manufacturer go global
There’s a particular kind of ingenuity that flourishes in regional Australia. Away from the noise of major business centres, founders build companies that quietly become world leaders in their field, solving deep specialised problems that global markets didn’t know could be solved. Modra Technology, based in Warragul in regional Victoria, is one of those companies.
